Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

This retrospective cohort study found that taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a reduced overall risk of cancer, including lower risks of endometrial, ...

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are ...

Serena Williams revealed how she turned her health around with the help of a GLP-1 medication after she struggled to lose ...

According to the National Institutes of Health, GLP-1, or Glucagon-like peptide-1, agonists are a class of medications utilised to treat type 2 diabetes mellitus (T2DM) and obesity. As a class of ...

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

USA: A recent study published in Diabetes, Obesity and Metabolism has reported that the use of glucagon-like peptide-1 ...

Ozempic and drugs like it have done wonders for weight loss by mimicking the natural hormone GLP-1 ( glucagon-like peptide-1 ...